HRTX — HERON THERAPEUTICS, INC. /DE/
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 818033 ·
Last close
$0.28
Market Cap
$53.70M
52W High
$1.58
52W Low
$0.26
ADV30
7,165,658
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 35,250,000 | 26,292,000 | -1,669,000 | -5,006,000 | 230,448,000 | 11,595,000 | 225,532,000 |
| Jun 2026 | 37,666,000 | 26,094,000 | -2,044,000 | -5,489,000 | 252,262,000 | 20,721,000 | 245,354,000 |
| Mar 2026 | 34,711,000 | 24,073,000 | -4,765,000 | -8,111,000 | 246,216,000 | 26,117,000 | 237,079,000 |
| Dec 2025 | 40,588,000 | 29,469,000 | 38,000 | -2,954,000 | 255,877,000 | 28,647,000 | 241,544,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-13,731,000
Investing CF
$434,000
Financing CF
$-18,176,000
CapEx
$-839,000
Dividends Paid
—
Buybacks
$-51,000
EPS Diluted TTM
$-0.12
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,953,389,000
Inventory
$90,585,000
Receivables
$89,571,000
ST Investments
$21,943,000
EBIT TTM
$-18,916,000
Pretax Income TTM
$-34,049,000
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$148,215,008
EBITDA
$-6,531,000
Free Cash Flow
$-12,147,625
Enterprise Value
$168,409,952
Total Cash
$23,449,000
Total Debt
$131,729,000
Shares Out
190,273,587
Trailing EPS
$-0.11
Book Value
$0.02
ROE
-217.8%
ROA
-2.2%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 154,904,000 | -2,538,000 | -20,195,000 | 255,877,000 | 241,544,000 | 14,333,000 | -27,591,000 |
| Dec 2024 | 144,285,000 | -11,528,000 | -13,580,000 | 233,147,000 | 266,798,000 | -33,651,000 | -22,529,000 |
| Dec 2023 | 127,044,000 | -110,615,000 | -110,559,000 | 222,506,000 | 256,479,000 | -33,973,000 | -58,789,000 |
| Dec 2022 | 107,672,000 | -174,658,000 | -182,024,000 | 250,951,000 | 237,379,000 | 13,572,000 | -146,912,000 |
TTM Snapshot
Revenues TTM
$151,178,000
NetIncome TTM
$-34,049,000
OpCashFlow TTM
—
Assets (Latest)
$252,262,000
Forward EPS
$-0.12
Max Pain — expiry 2026-12-18
max pain strike: $0.50 · spot: $0.27 · call oi: 3,439 · put oi: 119
Expected Move to 2026-12-18:
±$0.26
(96.30%) —
implied range
$0.01 –
$0.53
· ATM straddle on $0.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VRCA | Verrica Pharmaceuticals Inc. | $53.94M | $3.14 | — |
| IBO | IMPACT BIOMEDICAL INC. | $53.31M | $6.17 | — |
| XLO | Xilio Therapeutics, Inc. | $53.26M | $7.54 | — |
| INCR | Intercure Ltd. | $54.16M | $3.61 | — |
| XBIT | XBiotech Inc. | $54.27M | $1.78 | — |
News headlines (Yahoo Finance, 1h cache)
CorMedix Inc. Q3 2026 Earnings Call Summary
2026-11-12 18:03 · Yahoo
Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-12 12:30 · Yahoo
CorMedix to Acquire Heron Assets, Adding Four Products and Targeting Up to $60 Million in Savings
2026-11-10 11:12 · Yahoo
Heron Therapeutics Reports 7.8% Decline in Q3 Revenue to $35.3 Million and Announces Proposed Asset Sale
2026-11-09 15:43 · Yahoo
CorMedix stock gains as Heron deal adds four products
2026-11-09 13:59 · Yahoo
Heron Therapeutics Announces Third Quarter 2026 Financial Results
2026-11-09 13:30 · Yahoo
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
2026-11-09 13:25 · Yahoo
Heron Therapeutics: Q3 Earnings Snapshot
2026-11-09 13:23 · Yahoo
CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care
2026-11-09 12:15 · Yahoo
Heron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
2026-10-27 00:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.